| |
|
| |
| |
 |
| |
| Forthcoming events |
| On Wednesday, 20th March 2013, Duncan Curley will be speaking at the European Generic Medicines Association’s Annual Legal Affairs Forum in Brussels, Belgium on the proposals for a single European Patent Court. Please click here for further details. |
| |
| Previous events |
| DuncanCurley spoke at C5's Advanced Forum on multi-jurisdictional pharma / bio patent litigation on 17-18 February 2009 in Amsterdam. Please see: www.c5-online.com/intellectual_property/PatentLitigation for further details. |
| |
| On 14 May 2008, DuncanCurley ran a half day Executive Briefing on Patent Issues in the Development of Biosimilar Medicines, as part of the eleventh annual SMi Conference on Generics, Supergenerics and Patent Strategies in London (see photographs below). |
| |
Innovate Legal will re-run this workshop briefing, on request. For further details, please contact our Head of Projects,
SimonBarnham, either by email ( simonbarnham@innovatelegal.co.uk ) or by telephone (+44(0)20 7936 9286). For further details of the workshop programme, please see below. |
|
| |
| SESSION ONE |
| An overview of the commercial and regulatory landscape |
 |
The first wave of biosimilar medicines |
|
The second wave: 2010 and beyond |
|
Patent law basics |
|
|
|
| SESSION TWO |
| Erythropoietin |
|
Commercial overview |
|
The Dynepo® litigation |
|
Lessons from the public record: Aranesp® |
|
|
|
| SESSION THREE |
| Case Studies: insulin and G-CSF |
|
Recombinant insulin: commercial overview |
|
A closer look at insulin glargine |
|
G-CSF: commercial overview |
|
Lenograstim and PEGylated G-CSF (Neulasta®) |
|
|
|
|
|
|
| |
|
| [ Site Map ] |
|
